Monday, September 24, 2012
MorphoSys AG, of Martinsried, Germany, said results from a Phase Ib/IIa study demonstrated signs of efficacy with HuCAL antibody MORE103 in rheumatoid arthritis patients. The best response was achieved in the 1 mg/kg dose cohort, with an ACR20 sore of 68 percent at week four, which was significantly higher than in the control arm (p < 0.0001). Data also showed fast onset of action: Within two weeks, up to 40 percent of patients achieved an ACR20 score.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.